(Q36290931)

13 August 2017

1 reference

title

Eplerenone : a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure (English)

1 reference

13 August 2017

0 references

2

Greg L Plosker

1 reference

13 August 2017

Katherine F Croom

1

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

23

1 reference

13 August 2017

issue

10

1 reference

13 August 2017

page(s)

1057-1072

1 reference

Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction

13 August 2017

cites work

1 reference

12 December 2020

Evaluation of conflict of interest in economic analyses of new drugs used in oncology

1 reference

12 December 2020

A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort

1 reference

12 December 2020

Clinical epidemiology of heart failure: public and private health burden

1 reference

12 December 2020

1 reference

12 December 2020

Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials

1 reference

12 December 2020

Cost-effectiveness of captopril therapy after myocardial infarction.

1 reference

12 December 2020

An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry

1 reference

12 December 2020

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

12 December 2020

The epidemiology of heart failure secondary to coronary artery disease

1 reference

12 December 2020

Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction

1 reference

12 December 2020

Spironolactone in chronic heart failure:all's well that ends well

1 reference

12 December 2020

Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure

1 reference

12 December 2020

Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds

1 reference

12 December 2020

Epidemiology of myocardial infarction in France: Therapeutic and prognostic implications of heart failure during the acute phase

1 reference

12 December 2020

Economic burden of post-acute myocardial infarction heart failure in the United Kingdom

1 reference

12 December 2020

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors.

1 reference

12 December 2020

Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction

1 reference

12 December 2020

A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective

1 reference

12 December 2020

Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study

1 reference

12 December 2020

Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

1 reference

12 December 2020

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

12 December 2020

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

1 reference

12 December 2020

Health and economic benefits of increased beta-blocker use following myocardial infarction

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

1 reference

12 December 2020

Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective

1 reference

12 December 2020

Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction

1 reference

12 December 2020

Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE).

1 reference

12 December 2020

Characteristics and prognosis of patients with acute myocardial infarction in relation to occurrence of congestive heart failure

1 reference

12 December 2020

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure

1 reference

12 December 2020

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise th

1 reference

12 December 2020

Management of acute myocardial infarction in patients presenting with ST-segment elevation

1 reference

12 December 2020

Treatment of heart failure with spironolactone--trial and tribulations

1 reference

12 December 2020

Cost-effectiveness of eplerenone plus standard treatment compared with standard treatment in patients with myocardial infarction complicated by left ventricular systolic dysfunction and heart failure in the Netherlands

1 reference

12 December 2020

Burden and outcomes of hospitalisation for congestive heart failure

1 reference

12 December 2020

Publication bias in health economic studies

1 reference

12 December 2020

10.2165/00019053-200523100-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1052179231

0 references

1 reference